Parkinson Disease (PD)NCT07832695
Effects of Repetitive Transcranial Magnetic Stimulation (rTMS)-Primed Self-controlled Practice in People With Parkinson's Disease
A study testing Repetitive Transcranial Magnetic Stimulation (rTMS) and Physical therapy in people with Parkinson Disease (PD), run by National Taiwan University Hospital at 1 site in Taiwan.
Trial summary
Parkinson's disease (PD) is commonly associated with impaired motor learning and reduced motivation, both of which can negatively influence rehabilitation outcomes. Prior cross-sectional evidence suggests that providing individuals with PD self-controlled access to training parameters enhances motor learning… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Parkinson Disease (PD)
- What is being tested?
- Repetitive Transcranial Magnetic Stimulation (rTMS) and Physical therapy
- Type of treatment
- Medical device, Lifestyle or therapy programme
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 90 participants
- Where
- 1 siteTaiwan
- Study dates
- 23 Sep 2026to 31 Dec 2032
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- diagnosed of PD by neurologists and age above 18 years old
- able to follow the researcher's instruction (the Montreal Cognitive Assessment ≥ 24)
- able to stand and walk independently for 10 minutes with or without assistive devices
Who cannot join
- have neurological disorders other than PD (e.g., Parkinson plus syndrome, cognitive impairment, dementia, stroke)
- have contraindications to receive TMS, such as a pacemaker or deep brain stimulator implanted in the body
- a self-history of seizure or a family history of epilepsy
- pregnancy
- unstable medical conditions that is not under control
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Taiwan1 site, 1 recruiting
- Recruiting
School and Graduate Institute of Physical Therapy
Taipei, Zhongzheng Dist., 100
Jiu-Jenq Lin, PhD, +886-2-33668126, jiujlin@ntu.edu.tw
About this study
Official title: Effects of Repetitive Transcranial Magnetic Stimulation (rTMS)-Primed Self-controlled Practice on Motor Behavior, Psychosocial Functioning, and Neurophysiological Mechanisms in People With Parkinson's Disease
Parkinson's disease (PD) is commonly associated with impaired motor learning and reduced motivation, both of which can negatively influence rehabilitation outcomes. Prior cross-sectional evidence suggests that providing individuals with PD self-controlled access to training parameters enhances motor learning, increases motivation, and facilitates cognitive processing. However, the effects of self-controlled practice implemented across repeated training sessions remain underexplored. Moreover, given that dysfunction of fronto-striatal circuits in PD may limit the neuroplastic response to motor training alone, adjunctive neuromodulatory priming approaches such as repetitive transcranial magnetic stimulation (rTMS) may be required to optimize therapeutic efficacy. To date, it remains unclear whether rTMS priming combined with self-controlled motor training yields superior clinical benefits, and whether stimulation of different cortical targets produces differential effects. In particular, the dorsolateral prefrontal cortex (DLPFC), a key region involved in cognitive control and motivation, may offer distinct therapeutic effects compared with stimulation of the primary motor cortex (M1). This study aims to investigate the effects of rTMS priming over the DLPFC or M1, followed by self-controlled motor training, in individuals with PD, and to compare these effects with a sham stimulation condition.
This single-blinded, randomized control trial will recruit 90 individuals with PD, who will be matched into 45 pairs and randomly assigned to one of three stimulation conditions: DLPFC, M1, or sham. Within each pair, one participant will be allocated to a self-controlled practice condition, and the other to a yoked (paired-control) condition that receives identical training content determined by their matched counterpart. Each participant will undergo 12 intervention sessions. In each session, rTMS will be applied first as a priming intervention, followed immediately by 45 minutes of standardized physical therapy-based motor training. For the DLPFC group, stimulation will target the left DLPFC; for the M1 group, stimulation will be applied over the M1 contralateral to the more affected limb; and for the sham condition, the coil will be rotated 90 degrees to mimic stimulation without effective cortical activation. During the training phase, participants in the self-controlled condition will be allowed to select aspects of their practice content, whereas yoked participants will follow the corresponding selections made by their matched partner.
The primary outcome measure is the Unified Parkinson's Disease Rating Scale (UPDRS). Secondary outcomes include assessments of cognitive function, apathy, non-motor symptoms, gait performance, balance, functional mobility, falls efficacy, and quality of life. Neurophysiological outcomes will be assessed using single- and paired-pulse TMS to evaluate corticospinal excitability and cortico-cortical connectivity, particularly between DLPFC and M1 networks. All assessments will be conducted in the medication-on state by blinded evaluators at baseline, immediately post-intervention, and at one-month follow-up. Data will be analyzed using mixed-effects repeated-measures ANOVA to examine group-by-time interactions and intervention effects. This study seeks to determine whether rTMS priming over cognitive-control versus motor networks differentially enhances the efficacy of self-controlled motor training, and whether such combined interventions can induce sustained improvements in motor and non-motor outcomes in PD.
- Conditions
- Parkinson Disease (PD)
- Being tested
- Repetitive Transcranial Magnetic Stimulation (rTMS), Physical therapy
- Keywords
- Motor learning, Repetitive Transcranial Magnetic Stimulation (rTMS), Priming, Self-controlled practice
- Medical subject headings
- Parkinson Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Repetitive Transcranial Magnetic Stimulation (rTMS)Device
The iTBS paradigm will be used to prime the neuronal excitability of the DLPFC or M1 based on the group allocation. The patterns of iTBS are triplets of stimuli at 50Hz frequency repeated in 5Hz bursts with a 2 second train repeated every 10 seconds for a total of 190 seconds, which will result in 600 stimulation pulses. The intensity will be set at 80%-120% of motor threshold of the tibialis anterior (TA) or first dorsal interosseous (FDI) muscle of the more affected limb. As for the sham rTMS groups, the coil will be placed over the M1 hotspot but turned 90 degrees away so that the surface of the coil will be 90 degrees perpendicular to the scalp.
Physical therapyBehavioural
After the iTBS priming procedure, the participants will receive 45 minutes of one-on-one physical therapy training targeting whole body and lower extremity function. Each training session will involve flexibility exercise, gait training, balance training, resistance exercise, or cognitive-motor dual task training.
| Study group | Role | What they receive |
|---|---|---|
| DLPFC-self | Experimental | Not described Receives: Device: Repetitive Transcranial Magnetic Stimulation (rTMS); Behavioral: Physical therapy |
| DLPFC-yoked | Experimental | Not described Receives: Device: Repetitive Transcranial Magnetic Stimulation (rTMS); Behavioral: Physical therapy |
| M1-self | Experimental | Not described Receives: Device: Repetitive Transcranial Magnetic Stimulation (rTMS); Behavioral: Physical therapy |
| M1-yoked | Experimental | Not described Receives: Device: Repetitive Transcranial Magnetic Stimulation (rTMS); Behavioral: Physical therapy |
| Sham-self | Sham comparator | Not described Receives: Device: Repetitive Transcranial Magnetic Stimulation (rTMS); Behavioral: Physical therapy |
| Sham-yoked | Sham comparator | Not described Receives: Device: Repetitive Transcranial Magnetic Stimulation (rTMS); Behavioral: Physical therapy |
What is being measured
The primary outcome is the main question the study is designed to answer.
Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS)
The MDS-UPDRS is currently the gold-standard scale used in the clinics as well as research to determine the disease severity of PD. The MDS-UPDRS contains four parts: (1) non-motor aspects of experiences of daily living, (2) motor aspects of experiences of daily living, (3) motor examination, and (4) motor complications. Each item is scored from 0 (no symptom) to 4 (most severe symptom), and the total score range for the MDS-UPDRS is from 0 to 260 with a higher score indicates greater disease severity.
Measured: Three time points: pre-test (before intervention, 0 week), post-test (after all intervention sessions, up to 4 weeks), follow-up test (one month after intervention, up to 8 weeks)
Secondary outcomes (13)
Montreal cognitive assessment (MoCA)
The MoCA will be used to assess general cognitive function of the participants. It examines various cognitive functions, including set-shifting, visuospatial processing, abstract thinking, short-term memory, attention, verbal fluency, calculation, orientation, and digit span abilities. The total score of MoCA is 30 with a higher score suggests better cognitive function, and a score below 26 would suggest an increased risk of cognitive decline.
Measured: Three time points: pre-test (before intervention, 0 week), post-test (after all intervention sessions, up to 4 weeks), follow-up test (one month after intervention, up to 8 weeks)
Short-form Lille apathy rating scale (LARS)
The LARS scale has 12 items categorized into 7 domains: everyday productivity, interests, take the initiative, novelty seeking, motivation-voluntary actions, emotional responses, and social life. Each item is scored on a 5-point Likert scale or a binary yes/no scale. The score ranges from -15 to 15 with a higher score suggests more apathetic symptoms. It has been established that a short-form LARS score ≥ -7 points is the cut-off score for identifying apathy in PD.
Measured: Three time points: pre-test (before intervention, 0 week), post-test (after all intervention sessions, up to 4 weeks), follow-up test (one month after intervention, up to 8 weeks)
Non-motor symptoms scale for Parkinson's disease (NMSS)
The NMSS is a specifically designed 30-item scale to assess various non-motor symptoms of PD. It evaluates severity (score 0-3) and frequency (score 1-4) across nine non-motor domains: cardiovascular including falls, sleep/fatigue, mood /cognition, perceptual problems/hallucinations, attention/ memory, gastrointestinal tract, urinary, sexual function, and miscellaneous.
Measured: Three time points: pre-test (before intervention, 0 week), post-test (after all intervention sessions, up to 4 weeks), follow-up test (one month after intervention, up to 8 weeks)
Gait performances
To measure walking ability, the participants will be asked to walk along a 10-meter hallway with their comfortable walking speed and fastest walking speed in single- and dual-task conditions. The Physilog®5 system (Gait Up, Renens, Switzerland) including two inertial sensors with built-in 3D accelerometers and gyroscopes will be fixated to the shoelaces area of both feet to record the walking data. The data will be sampled at a rate of 128Hz and will then be analysed by the Gait Up© gait analysis package (Gait Up SA, Switzerland). Gait parameters of interest include velocity, step length, cadence, foot-strike angle, and foot clearance.
Measured: Three time points: pre-test (before intervention, 0 week), post-test (after all intervention sessions, up to 4 weeks), follow-up test (one month after intervention, up to 8 weeks)
New freezing of gait questionnaire (NFOG-Q)
The NFOG-Q is a self-reported questionnaire to determine the presence and severity of freezing of gait in people with PD. It contains 9 questions with the first question asking the participants whether they have experienced freezing episodes in the past 1 month. If an individual answers 'no' to this question, he/she will be classified as non-freezer and will not need to answer the following questions. One the other hand, if a person answers 'yes' to the first question, he/she will be asked to further complete the rest of the questions regarding the severity and duration of the freezing episodes.
Measured: Three time points: pre-test (before intervention, 0 week), post-test (after all intervention sessions, up to 4 weeks), follow-up test (one month after intervention, up to 8 weeks)
5-time sit to stand test (5TSTS)
The 5TSTS will be used to evaluate the lower extremity muscle strength and endurance. Using a standardized chair, the participants will be requested to stand up and then sit down as quickly as possible for 5 times, and the time to complete the test will be recorded.
Measured: Three time points: pre-test (before intervention, 0 week), post-test (after all intervention sessions, up to 4 weeks), follow-up test (one month after intervention, up to 8 weeks)
Timed up and go (TUG) test
The TUG is a gold standard to measure dynamic balance and gait ability. The participant will first sit on a standardized chair with back supported. After a GO signal, he/she will stand up, walk 3 meters, turn 180°, walk back and then sit down. The participants will be instructed to walk with their preferred and fastest walking speeds.
Measured: Three time points: pre-test (before intervention, 0 week), post-test (after all intervention sessions, up to 4 weeks), follow-up test (one month after intervention, up to 8 weeks)
Mini balance evaluation systems test (Mini-BESTest)
The Mini-BESTest assesses 4 aspects of balance ability, including anticipatory postural adjustments, reactive postural control, sensory orientation, and dynamic gait. It contains 14 items, and each item is scored on a 0-2 ordinal scale, with a total score of 28 points. A higher score indicates better balance control.
Measured: Three time points: pre-test (before intervention, 0 week), post-test (after all intervention sessions, up to 4 weeks), follow-up test (one month after intervention, up to 8 weeks)
Activities-Specific Balance Confidence (ABC) scale
The ABC scale will be utilized to assess an individual's confidence level of not falling when performing daily activities at home and in the community. Sixteen indoor and outdoor activities are involved in the scale, and the participants will rate their confidence level of not falling from 0 (no confidence at all) to 100 (very confident) when performing the activities. An average score of these questions will then be calculated with a higher score suggests greater confidence of not falling.
Measured: Three time points: pre-test (before intervention, 0 week), post-test (after all intervention sessions, up to 4 weeks), follow-up test (one month after intervention, up to 8 weeks)
Parkinson's Disease Questionnaire-39 (PDQ-39)
The PDQ-39 is a specifically designed self-report questionnaire to determine quality of life in individuals with PD. The questionnaire contains 39 health-related items, and the participants will answer these questions based on their own experience in the past one month. Each item is score on a 5-point Likert scale with a lower score suggests less difficulty performing the task. As a result, a lower total score will indicate better quality of life.
Measured: Three time points: pre-test (before intervention, 0 week), post-test (after all intervention sessions, up to 4 weeks), follow-up test (one month after intervention, up to 8 weeks)
Motivation questionnaire
The motivational questionnaire will be used to determine their motivation level after each training session. It consists of perceived competence, task interest/enjoyment, and autonomy. The questions for perceived competence and task interest/enjoyment are directly taken from Intrinsic Motivation Inventory (IMI), which originally consists of 22 items with 4 subscales including interest/enjoyment, perceived competence, perceived choice, and pressure/tension (McAuley et al., 1989). As for autonomy, the questions are referenced from the autonomy subscale used in a study by Carter and Ste-Marie (Carter \& Ste-Marie, 2017b). The motivational questionnaire used in this study consists of 21 items scored with a 7-point Likert scale with a higher score indicates better in perceived competence, task interest/enjoyment, and autonomy.
Measured: Three time points: pre-test (before intervention, 0 week), post-test (after all intervention sessions, up to 4 weeks), follow-up test (one month after intervention, up to 8 weeks)
Corticomotor excitability
Transcranial magnetic stimulation (TMS) device (The Magstim Company Ltd, Whitland, UK) will be used to determine the neurophysiology of corticomotor excitability.
Measured: Three time points: pre-test (before intervention, 0 week), post-test (after all intervention sessions, up to 4 weeks), follow-up test (one month after intervention, up to 8 weeks)
Cortico-cortical connectivity
Transcranial magnetic stimulation (TMS) device (The Magstim Company Ltd, Whitland, UK) will be used to determine the neurophysiology of corticocortical connectivity.
Measured: Three time points: pre-test (before intervention, 0 week), post-test (after all intervention sessions, up to 4 weeks), follow-up test (one month after intervention, up to 8 weeks)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Sep 2026
- Study start23 Sep 2026 (estimated)
- Primary completion31 Dec 2031 (estimated)
- Study completion31 Dec 2032 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for Parkinson Disease (PD)Studies of the same condition, open and under way.
- More trials run by National Taiwan University HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Factorial
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 90 participants (estimated)
Sponsor and investigators
- Lead sponsor
- National Taiwan University Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Graduate Institute of Physical Therapy, Principal investigator, National Taiwan University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07832695
- Sponsor's protocol ID
- 202601081DINC
- Status last verified
- Sep 2026
- First submitted
- 15 Sep 2026
- Last updated
- 22 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
De-Jun Lim. Effects of Autonomy on Motor Learning in People with Parkinson's Disease. 2024. doi:10.6342/NTU202401486. uri:http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/94704
Chung CL, Mak MK, Hallett M. Transcranial Magnetic Stimulation Promotes Gait Training in Parkinson Disease. Ann Neurol. 2020 Nov;88(5):933-945. doi: 10.1002/ana.25881. Epub 2020 Sep 8.
PubMed 32827221Yang YR, Tseng CY, Chiou SY, Liao KK, Cheng SJ, Lai KL, Wang RY. Combination of rTMS and treadmill training modulates corticomotor inhibition and improves walking in Parkinson disease: a randomized trial. Neurorehabil Neural Repair. 2013 Jan;27(1):79-86. doi: 10.1177/1545968312451915. Epub 2012 Jul 10.
PubMed 22785003
Study at a glance
From the registry record, last updated by the sponsor on 22 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effects of Repetitive Transcranial Magnetic Stimulation (rTMS)-Primed Self-controlled Practice on Motor Behavior, Psychosocial Functioning, and Neurophysiological Mechanisms in People With Parkinson's Disease
- ClinicalTrials.gov ID
- NCT07832695
- Acronym / sponsor ID
- 202601081DINC
- Conditions
- Parkinson Disease (PD)
- Keywords
- Motor learning, Repetitive Transcranial Magnetic Stimulation (rTMS), Priming, Self-controlled practice
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 90 participants (estimated)
- Lead sponsor
- National Taiwan University HospitalUniversity, hospital or other
- Study start
- 23 Sep 2026 (estimated)
- Primary completion
- 31 Dec 2031 (estimated)
- Study completion
- 31 Dec 2032 (estimated)
- First posted
- 22 Sep 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Parkinson's disease (PD) is commonly associated with impaired motor learning and reduced motivation, both of which can negatively influence rehabilitation outcomes. Prior cross-sectional evidence suggests that providing individuals with PD self-controlled access to training parameters enhances motor learning, increases motivation, and facilitates cognitive processing. However, the effects of self-controlled practice implemented across repeated training sessions remain underexplored. Moreover, given that dysfunction of fronto-striatal circuits in PD may limit the neuroplastic response to motor training alone, adjunctive neuromodulatory priming approaches such as repetitive transcranial magnetic stimulation (rTMS) may be required to optimize therapeutic efficacy. To date, it remains unclear whether rTMS priming combined with self-controlled motor training yields superior clinical benefits, and whether stimulation of different cortical targets produces differential effects. In particular, the dorsolateral prefrontal cortex (DLPFC), a key region involved in cognitive control and motivation, may offer distinct therapeutic effects compared with stimulation of the primary motor cortex (M1). This study aims to investigate the effects of rTMS priming over the DLPFC or M1, followed by self-controlled motor training, in individuals with PD, and to compare these effects with a sham stimulation condition.
This single-blinded, randomized control trial will recruit 90 individuals with PD, who will be matched into 45 pairs and randomly assigned to one of three stimulation conditions: DLPFC, M1, or sham. Within each pair, one participant will be allocated to a self-controlled practice condition, and the other to a yoked (paired-control) condition that receives identical training content determined by their matched counterpart. Each participant will undergo 12 intervention sessions. In each session, rTMS will be applied first as a priming intervention, followed immediately by 45 minutes of standardized physical therapy-based motor training. For the DLPFC group, stimulation will target the left DLPFC; for the M1 group, stimulation will be applied over the M1 contralateral to the more affected limb; and for the sham condition, the coil will be rotated 90 degrees to mimic stimulation without effective cortical activation. During the training phase, participants in the self-controlled condition will be allowed to select aspects of their practice content, whereas yoked participants will follow the corresponding selections made by their matched partner.
The primary outcome measure is the Unified Parkinson's Disease Rating Scale (UPDRS). Secondary outcomes include assessments of cognitive function, apathy, non-motor symptoms, gait performance, balance, functional mobility, falls efficacy, and quality of life. Neurophysiological outcomes will be assessed using single- and paired-pulse TMS to evaluate corticospinal excitability and cortico-cortical connectivity, particularly between DLPFC and M1 networks. All assessments will be conducted in the medication-on state by blinded evaluators at baseline, immediately post-intervention, and at one-month follow-up. Data will be analyzed using mixed-effects repeated-measures ANOVA to examine group-by-time interactions and intervention effects. This study seeks to determine whether rTMS priming over cognitive-control versus motor networks differentially enhances the efficacy of self-controlled motor training, and whether such combined interventions can induce sustained improvements in motor and non-motor outcomes in PD.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Factorial
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 6
| Arm | Type | Receives |
|---|---|---|
| DLPFC-self | Experimental | Device: Repetitive Transcranial Magnetic Stimulation (rTMS), Behavioral: Physical therapy |
| DLPFC-yoked | Experimental | Device: Repetitive Transcranial Magnetic Stimulation (rTMS), Behavioral: Physical therapy |
| M1-self | Experimental | Device: Repetitive Transcranial Magnetic Stimulation (rTMS), Behavioral: Physical therapy |
| M1-yoked | Experimental | Device: Repetitive Transcranial Magnetic Stimulation (rTMS), Behavioral: Physical therapy |
| Sham-self | Sham comparator | Device: Repetitive Transcranial Magnetic Stimulation (rTMS), Behavioral: Physical therapy |
| Sham-yoked | Sham comparator | Device: Repetitive Transcranial Magnetic Stimulation (rTMS), Behavioral: Physical therapy |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- diagnosed of PD by neurologists and age above 18 years old
- able to follow the researcher's instruction (the Montreal Cognitive Assessment ≥ 24)
- able to stand and walk independently for 10 minutes with or without assistive devices
Key exclusion criteria (5 listed)
- have neurological disorders other than PD (e.g., Parkinson plus syndrome, cognitive impairment, dementia, stroke)
- have contraindications to receive TMS, such as a pacemaker or deep brain stimulator implanted in the body
- a self-history of seizure or a family history of epilepsy
- pregnancy
- unstable medical conditions that is not under control
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Repetitive Transcranial Magnetic Stimulation (rTMS)The iTBS paradigm will be used to prime the neuronal excitability of the DLPFC or M1 based on the group allocation. The patterns of iTBS are triplets of stimuli at 50Hz frequency repeated in 5Hz bursts with a 2 second train repeated every 10 seconds for a total of 190 seconds, which will result in 600 stimulation pulses. The intensity will be set at 80%-120% of motor threshold of the tibialis anterior (TA) or first dorsal interosseous (FDI) muscle of the more affected limb. As for the sham rTMS groups, the coil will be placed over the M1 hotspot but turned 90 degrees away so that the surface of the coil will be 90 degrees perpendicular to the scalp. | Device | DLPFC-self, DLPFC-yoked, M1-self, M1-yoked, Sham-self, Sham-yoked |
| Physical therapyAfter the iTBS priming procedure, the participants will receive 45 minutes of one-on-one physical therapy training targeting whole body and lower extremity function. Each training session will involve flexibility exercise, gait training, balance training, resistance exercise, or cognitive-motor dual task training. | Behavioural | DLPFC-self, DLPFC-yoked, M1-self, M1-yoked, Sham-self, Sham-yoked |
Primary outcome
Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS)
Time frame: Three time points: pre-test (before intervention, 0 week), post-test (after all intervention sessions, up to 4 weeks), follow-up test (one month after intervention, up to 8 weeks)
The MDS-UPDRS is currently the gold-standard scale used in the clinics as well as research to determine the disease severity of PD. The MDS-UPDRS contains four parts: (1) non-motor aspects of experiences of daily living, (2) motor aspects of experiences of daily living, (3) motor examination, and (4) motor complications. Each item is scored from 0 (no symptom) to 4 (most severe symptom), and the total score range for the MDS-UPDRS is from 0 to 260 with a higher score indicates greater disease severity.
13 secondary outcomes
Montreal cognitive assessment (MoCA)
Time frame: Three time points: pre-test (before intervention, 0 week), post-test (after all intervention sessions, up to 4 weeks), follow-up test (one month after intervention, up to 8 weeks)
Short-form Lille apathy rating scale (LARS)
Time frame: Three time points: pre-test (before intervention, 0 week), post-test (after all intervention sessions, up to 4 weeks), follow-up test (one month after intervention, up to 8 weeks)
Non-motor symptoms scale for Parkinson's disease (NMSS)
Time frame: Three time points: pre-test (before intervention, 0 week), post-test (after all intervention sessions, up to 4 weeks), follow-up test (one month after intervention, up to 8 weeks)
Gait performances
Time frame: Three time points: pre-test (before intervention, 0 week), post-test (after all intervention sessions, up to 4 weeks), follow-up test (one month after intervention, up to 8 weeks)
New freezing of gait questionnaire (NFOG-Q)
Time frame: Three time points: pre-test (before intervention, 0 week), post-test (after all intervention sessions, up to 4 weeks), follow-up test (one month after intervention, up to 8 weeks)
5-time sit to stand test (5TSTS)
Time frame: Three time points: pre-test (before intervention, 0 week), post-test (after all intervention sessions, up to 4 weeks), follow-up test (one month after intervention, up to 8 weeks)
Timed up and go (TUG) test
Time frame: Three time points: pre-test (before intervention, 0 week), post-test (after all intervention sessions, up to 4 weeks), follow-up test (one month after intervention, up to 8 weeks)
Mini balance evaluation systems test (Mini-BESTest)
Time frame: Three time points: pre-test (before intervention, 0 week), post-test (after all intervention sessions, up to 4 weeks), follow-up test (one month after intervention, up to 8 weeks)
Activities-Specific Balance Confidence (ABC) scale
Time frame: Three time points: pre-test (before intervention, 0 week), post-test (after all intervention sessions, up to 4 weeks), follow-up test (one month after intervention, up to 8 weeks)
Parkinson's Disease Questionnaire-39 (PDQ-39)
Time frame: Three time points: pre-test (before intervention, 0 week), post-test (after all intervention sessions, up to 4 weeks), follow-up test (one month after intervention, up to 8 weeks)
Motivation questionnaire
Time frame: Three time points: pre-test (before intervention, 0 week), post-test (after all intervention sessions, up to 4 weeks), follow-up test (one month after intervention, up to 8 weeks)
Corticomotor excitability
Time frame: Three time points: pre-test (before intervention, 0 week), post-test (after all intervention sessions, up to 4 weeks), follow-up test (one month after intervention, up to 8 weeks)
Cortico-cortical connectivity
Time frame: Three time points: pre-test (before intervention, 0 week), post-test (after all intervention sessions, up to 4 weeks), follow-up test (one month after intervention, up to 8 weeks)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Sep 2026.
- Results publicationDe-Jun Lim. Effects of Autonomy on Motor Learning in People with Parkinson's Disease. 2024. doi:10.6342/NTU202401486. uri:http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/94704
- Results publication: PubMed 32827221Chung CL, Mak MK, Hallett M. Transcranial Magnetic Stimulation Promotes Gait Training in Parkinson Disease. Ann Neurol. 2020 Nov;88(5):933-945. doi: 10.1002/ana.25881. Epub 2020 Sep 8.
- Results publication: PubMed 22785003Yang YR, Tseng CY, Chiou SY, Liao KK, Cheng SJ, Lai KL, Wang RY. Combination of rTMS and treadmill training modulates corticomotor inhibition and improves walking in Parkinson disease: a randomized trial. Neurorehabil Neural Repair. 2013 Jan;27(1):79-86. doi: 10.1177/1545968312451915. Epub 2012 Jul 10.
- Individual participant dataSharing planned: No
Related trials for Parkinson Disease (PD)
RecruitingPhase 3
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
Cervical Cancer
Active, not recruitingPhase 1/2
Clinical Safety and Efficacy of Umbilical Cord Mesenchymal Stromal Cells-derived Exosomes in Patients With Parkinson's Disease
Parkinson Disease (PD)
Active, not recruitingObservational study
Adaptive DBS to Offset STN Dysregulation During Exercise in PD
Parkinson Disease
Not yet recruiting
Evaluating the Effect of the Zeen Mobility Device on Clinical Practicality, Safety, and Impact (Via Assessments of Walking, Standing Tolerance, Balance, Endurance, Effort, and Participation in Daily Tasks) in an Outpatient Rehabilitation Setting for Individuals With Mobility Impairments.
Stroke, Parkinson's Disease (PD)
Active, not recruitingPhase 2
A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)
Carcinoma, Non-Small-Cell Lung
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Graduate Institute of Physical Therapy principal investigator
National Taiwan University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Repetitive Transcranial Magnetic Stimulation (rTMS) and Physical therapy in people with Parkinson Disease (PD), run by National Taiwan University Hospital at 1 site in Taiwan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 22 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Taiwan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Ya-Yun Lee, PhD (+886-2-33668155, yayunlee@ntu.edu.tw), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) (time frame: Three time points: pre-test (before intervention, 0 week), post-test (after all intervention sessions, up to 4 weeks), follow-up test (one month after intervention, up to 8 weeks)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07832695, which also lists 3 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Sep 2026.